Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Organization

Heard in 2 episodes across 1 show since Aug 2026

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing novel cardiopulmonary therapies. The company's primary development programs target pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

Episodes

2
across 1 show

First heard

Aug 2026

Expert statements

2
2 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20262
Sep 20260
Oct 20260

What experts have said about Tenax Therapeutics, Inc.

2 statements · 2 negative

  1. Emily GraffeoNegativeAug 10, 2026· Stock Movers

    Tenax Therapeutics shares fell more than 90% in one day.

    “the shares plummeted over 90% today.”

    Listen at 3:39

    Open the episode · Berkshire Jumps, Monday.com Falls, Tenax Plummets
  2. Emily GraffeoNegativeAug 10, 2026· Stock Movers

    Tenax Therapeutics has about $50 million market capitalization after erasing roughly $450 million.

    “It's Only now about $50 million in market cap but of course it had erased about 450 million.”

    Listen at 4:18

    Open the episode · Berkshire Jumps, Monday.com Falls, Tenax Plummets
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Tenax Therapeutics, Inc., newest first

Tenax Therapeutics, Inc. · PodLume